Lamictal Antitrust Litigation

Case Name:   In re: Lamictal Indirect Purchaser 
                        Antitrust and Consumer Litigation
Court:             United States District Court 
                             for the District of New Jersey
Status:           Settled

This case alleges that GlaxoSmithKline and Teva Pharmaceuticals conspired to delay entry of generic and less expensive formulations of Lamicatal®-brand lamotrigine tablets in violate of the federal antitrust laws and state consumer protection statutes.  The plaintiffs are consumers and union health and welfare fund payers of branded and generic formulations of Lamicatal®.  The case was filed and seeks to be certified as a class action and is pending in the United States District Court for the District of New Jersey. 

View the Complaint

News: 
GSK, Indirect Purchasers Plan to Settle Pay-For-Delay Suit Class  
(Law 360, July 15, 2016)